Kornimate/medical-research-clean huggingface dataset:
dynamic plantar pressures changes after dry needling in flexor digitorum brevis versus non emission laser

Conditions: Flatfoot

Summary: thirty-six subjects randomly distributed between a dry needling intervention group and a control group whose intervention is a non-emission laser. all the subjects will be measured before and after the interventions of each group. the measurements will be made on a pressure platform to record the dynamic footprint variables.

thirty-six subjects randomly distributed between a dry needling intervention group and a control group whose intervention is a non-emission laser. all the subjects will be measured before and after the interventions of each group. the measurements will be made on a pressure platform to record the dynamic footprint variables of the first step of both feet.

Eligibility criteria:
inclusion criteria: * individuals must have latent trigger point in flexor brevis digitorum muscles with no other pathologies exclusion criteria: * previous lower extremities surgery. * history of lower extremities injury with residual symptoms (pain, "giving-away" sensations) within the last year. * leg-length discrepancy more than 1 cm * balance deficits (determined by oral questionnaire regarding falls)

Keywords: foot gait dry needling trigger point
dry needling and maitland joint mobilization techniques in patients with myofacial chronic neck pain

Conditions: Myofacial Pain; Neck Pain

Summary: the purpose of my research is to compare the effects of dry needling and maitland mobilization in chronic myofacial neck pain

to distinguish which technique is most effective in pain reduction and range gain because in chronic cases there is involvement of fascia, muscles and joints due to prolonged stress on any of the component affecting the other. hence, the study will help to design a treatment plan with more accurate intervention. after sample collection according to selection criteria treatment sessions will be given to both groups for 6 weeks. data will be collected at baseline, then after 2 weeks, 4 weeks and at 8th week. tools for data collection are visual analogue scale, neck disability index and goniometer. for statistical analysis spss 22 will be used. intra group difference will be calculated by repeated measurement anova / friedman test and inter group analysis will be done by independent sample t test. descriptive data will be expressed in terms of frequency and proportions.

Eligibility criteria:
inclusion criteria: * bilateral pain involving the upper trapezius and elevator muscle of the scapula; * duration of pain of at least 3 months; * a pain intensity corresponding to at least 20 mm on a 100 mm visual analogue scale (vas) * neck pain with symptoms provoked by either neck postures or neck movement; * pain localized at least in the cervical and occipital regions but not in the orofacial region; * neck disability index (ndi) greater than or equal to 15 points; * restricted cervical range of movements (flexion, extension, rotation, and sidebending); (i) presence of bilateral mtrps in upper trapezius and levator scapulae muscles exclusion criteria: * any signs, symptoms, or history of the following diseases: * orofacial pain and temporo-mandibular disorders * a history of traumatic injuries (e.g., contusion, fracture, and whiplash injury); * systemic diseases such as fibromyalgia, systemic erythematous lupus, and arthritis; (d) neurologic disorders (e.g., trigeminal neuralgia or occipital neuralgia); * concomitant medical diagnosis of any primary headache (tension type or migraine); * unilateral neck pain; * cervical spine surgery; * clinical diagnosis of cervical radiculopathy or myelopathy; * needle phobia; * history of previous physical therapy intervention for the cervical region in last 6 months.

Keywords: neck pain myofacial pain
comparison between two techniques used in treatment of long anterior urethral stricture

Conditions: Urethral Stricture, Male

Summary: to evaluate dorsolateral and dorsal approach urethroplasty in treatment of anterior urethral stricture by using buccal mucosal graft as regard voiding and sexual outcomes.

at the department of urology, sohag university hospital, both techniques of dorsolateral and dorsal approach urethroplasty in treatment of anterior urethral stricture by using buccal are used in repair of long stricture anterior urethra.therefore, our data can be used as a source for the comparative analysis of these two buccal mucosa graft urethroplasty techniques.this study aimed to compare these procedures to determine their advantages and disadvantages, as regard voiding ,sexual function and quality of life after the surgery.

Eligibility criteria:
inclusion criteria: * long anterior urethral stricture exclusion criteria: * children. * recurrent stricture
risk adapted spinal cord/cauda constraint relaxation for high-risk patients with metastatic epidural spinal cord compression undergoing spine stereotactic radiosurgery

Conditions: Spinal Cord; Metastatic Epidural; Spine Stereotactic

Summary: to learn about the safety of a procedure called cord dose escalated spine stereotactic radiosurgery (cde-ssrs) in patients with mescc.

primary objectives the primary protocol objectives are to establish the safety of cde-ssrs alone in participants with mescc. specifically, we aim to maintain an rm risk no greater than 1%. rm will be defined as non-functional paresis per the mccormick score (i.e., grade d). secondary objectives secondary objectives include pain control as measured by the brief pain inventory, quality of life as measured by the eq-5d, symptom burden as measured by the mdasi-sp, overall survival, toxicity, ambulatory rate and cost-effectiveness. lc will be defined radiographically with serial mri scans by the study radiologist per spino criteria.

Eligibility criteria:
inclusion criteria: 1. greater than or equal to 18 years old 2. radiographically documented spinal metastasis on spine mri within 4 weeks of registration 3. proximity of spinal metastasis to spinal cord or cauda equina which precludes achieving a gtv dmin of at least 14 gy per the pi 4. all participants must be able to receive single fraction ssrs at the site of interest with 0.01 cc of the spinal cord receiving 14-16 gy and/or 0.01 cc of the cauda equina receiving 18-20 gy. the goal of treatment is to select the minimal dose to the organ at risk which will achieve a gtv dmin of 14 gy at the treating physician's discretion. 5. maximum of 3 contiguous vertebral levels involved with metastasis in the spine to be irradiated in a single session 6. all participants must be able to receive a single fraction spine radiosurgery at the designated site of interest to at least a dose of 18 gy 7. all participants must have a vertebral level site of interest from c1 to s2 8. signed informed consent 9. diagnosis of cancer excluding ultra-radiosensitive histologies (see 4.2) 10. motor strength ≥ 4 out of 5 in extremity or extremities affected by the level of cord compression 11. ecog ≤ 2 exclusion criteria: 1. participants with ultra-radiosensitive histologies (lymphoma, multiple myeloma/plasmacytoma) 2. prior history of radiation at the spinal site of interest 3. inability to lie supine comfortably for ≥ 60 minutes 4. progressive neurological deficits due to compression 5. inability of obtain an mri 6. inability or refusal to undergo an mr simulation 7. no eligible for single fraction ssrs for any reason 8. participants who are pregnant
irrigation versus no irrigation for perforated appendicitis

Conditions: Perforated Appendicitis

Summary: the purpose is to quantify the effect of irrigation during laparoscopic appendectomy for perforated appendicitis.

this will be a prospective, randomized clinical trial involving patients who present to the hospital with perforated appendicitis. this will be a definitive study. power calculation was based on abscess rate in the previous prospective study. an unacceptable abscess rate needed to be chosen. our current rate is 20%, or one-fifth of the patients. if this were to increase by 15%, it would place just over one third of the patients at risk which would be unacceptable. this is comparable to the 36% rejection level we used for the previous irb approved trial (#07 02-031). using a delta of 0.15 with alpha of 0.05 and power of 0.8, the sample size is 109 patients in each arm. therefore we will anticipate enrolling 220. subjects will be those children who are found to have severe inflammatory changes on imaging or a high clinical suspicion of perforation. permission will be obtained from parents prior to the operation. all of these children will be under duress prior to randomization, therefore we request waiving assent as we have done with the previous perforated appendicitis studies. the final decision to include a child in the study will made after perforation has been visually confirmed during surgery. perforation will be defined as an identifiable hole in the appendix or stool in the abdomen. the randomization assignment will be made known at the initiation of the operation, and confirmation of perforation will confirm the patient will utilize the next randomization slot. the irrigation group will have suction irrigator set up with a 1 liter bag of normal saline. the surgeon must use at least 500 ml of this bag but may use as much as they choose. the no irrigation group will have the suction irrigator set up without the saline attachment. this will leave them with the capacity for suction only. since several suction devices exist, this will assure the same type of suction for both groups. after the operation, both groups will be managed in the same manner. when the patient is tolerating a regular diet, on oral pain medication and has been afebrile for over 12 hours, they will be discharged on oral antibiotics to complete a course of 7 days. if they stay until the 5th post-operative day, a white blood cell count will be checked, which if it is normal, they will be discharged to home without antibiotics. this is standard post-operative care as delineated by our previous prospective, randomized.

Eligibility criteria:
inclusion criteria: * under 18 yrs old * perforation identified as hole in the appendix or fecalith in the abdomen exclusion criteria: * no perforation * a significant comorbidity that would limit their ability to recover from appendectomy in a normal fashion

Keywords: perforated appendicitis laparoscopic appendectomy children irrigation
clinical pharmacology study of brentuximab vedotin (sgn-35)

Conditions: Carcinomas; Disease, Hodgkin; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms

Summary: the purpose of this study is to identify brentuximab vedotin drug-drug interactions in patients with cd30-positive cancers and to determine the main route of excretion. the study will also assess blood drug levels in patients with renal or hepatic impairment (special populations).


Eligibility criteria:
inclusion criteria: * adequate organ function (special populations: serum bilirubin \>2 mg/dl or creatinine clearance \<50 ml/min) * ecog performance status \<2 (special populations: \<4) * relapsed or refractory cd30-positive malignancy exclusion criteria: * receiving prohibited medication within 4 weeks * poor liver function (child-pugh class c) * current diagnosis of primary cutaneous alcl * acute or chronic graft-versus-host disease

Keywords: antibody-drug conjugate antigens, cd30 disease, hodgkin lymphoma, large-cell, anaplastic lymphoma, non-hodgkin monomethyl auristatin e drug therapy immunotherapy hematologic diseases lymphoma antibodies, monoclonal
effect of hfr-supra in the treatment of multiple myeloma-related acute kidney injury

Conditions: Multiple Myeloma; Acute Kidney Injury; Hemodiafiltration With Ultrafiltrate Regeneration (HFR)

Summary: in patients with multiple myeloma-related acute kidney injury, compare the renal outcome of chemotherapy combined with hfr-supra to chemotherapy combined with hemodialysis.

in patients with multiple myeloma-related severe acute kidney injury, compare the renal outcome between patients receiving hfr-supra and patients receiving hemodialysis. both groups of patients receive chemotherapy.

Eligibility criteria:
inclusion criteria: * 18 to 80 years old * new onset of multiple myeloma * acute kidney injury with egfr \< 15 ml/min/1.73m2 and need hemodialysis * biopsy-proven cast nephropathy or clinical diagnosis of cast nephropathy based on exclusion of other causes of acute kidney injury including post-renal obstruction, hypercalcaemia, amyloidosis, light-chain deposition disease, contrast media and drug nephropathy * serum light chain \> 500 mg/l exclusion criteria: * chronic kidney disease stage 3 to 5 (egfr\< 60 ml/min/1.73m2 for at least 3 months) * haemodynamics unstability * active bleeding * cardiovascular and cerebrovascular events in the last month * other malignant tumor * conditions not suitable to participate in the study, such as bad compliance
toradol v. celecoxib for postoperative pain

Conditions: Pain, Postoperative

Summary: randomized control trial between ketorolac versus celecoxib for postoperative pain following hysterectomy.

purpose: to determine if celebrex (celecoxib) is as effective as toradol (ketorolac) at controlling postoperative pain when given in addition to standard postoperative pain control regimens. rationale: toradol (ketorolac) is currently used by many surgeons as adjuvant therapy in addition to standard narcotics in managing immediate postoperative pain. toradol (ketorolac) is a non-steroidal anti-inflammatory drug that acts as a non-selective cyclooxygenase (cox), inhibiting cox-1 and cox-2 isoforms. (toradol) ketorolac has been associated with significant complications including postoperative bleeding and acute renal insufficiency. celebrex (celecoxib) is a selective cox-2 inhibitor that has been associated with adverse cardiovascular outcomes in patients with pre-existing cardiac disease but not with postoperative bleeding or renal insufficiency. celebrex (celecoxib) has also been shown to control postoperative pain but has never been compared to toradol (ketorolac). population: patients undergoing hysterectomy on the gynecology oncology service. design: randomized control trial. procedures: all patients will receive a standard postoperative pain regimen with oral tylenol (acetaminophen), oral lortab (hydrocodone/acetaminophen) as needed, and iv dilaudid (hydromorphone) as needed. randomization: each participant will be assigned a number using a random number generator for assignment to one of the two postoperative pain regimens: arm 1: patients ages 18-65 will receive iv toradol (ketorolac) 30mg q6 hrs after their operation for 48 hrs or until hospital discharge if patients are discharged home in less than 48 hours after their operation. \*\*patients over age 65 will receive iv toradol (ketorolac) 15mg q6hrs instead of 30mg arm 2: patients who will receive oral celebrex (celecoxib) 400mg 1 hour prior to their procedure then 200mg oral twice daily for a total of seven days. patients discharged prior to 7 days will be given a prescription for celebrex (celecoxib) to complete a total of 7 days. following surgery all patients will be given a postoperative questionnaire at the day of surgery, which was returned at the two week postoperative visit, examining time until return to adls, days of narcotic use, and number of narcotic pills used.

Eligibility criteria:
inclusion criteria: * patients undergoing hysterectomy exclusion criteria: * coronary artery disease * peptic ulcer disease * chronic renal disease * liver disease * alcohol abuse * daily narcotic usage * narcotic use 24 hours prior to surgery * crohn's disease * history of myocardial infarction * history of stroke * preoperative hematocrit less than 24 * asthma * ulcerative colitis * diverticulitis * aspirin allergy * sulfonamide allergy * pre-operative pain score of greater than 3 * patients undergoing procedures that may involve bowel resection or bowel reanastomosis. * allergy to any non-steroidal anti-inflammatory drug * cardiac anomaly or disease * congestive heart failure
glucose disposal rate as a metric for detection of metabolic associated fatty liver

Conditions: MAFLD

Summary: a 12-month prospective observational cohort study assessing egdr's utility in diagnosing mafld (via fibroscan® cap ≥248 db/m) and correlating it with steatosis/fibrosis severity. secondary aims compare egdr to fli/fib-4 scores and identify optimal diagnostic cut-offs

primary aim determine egdr's diagnostic accuracy for mafld using fibroscan® (cap ≥248 db/m) as the gold standard. secondary aims correlate egdr with mafld severity (steatosis via cap, fibrosis via liver stiffness measurement \[lsm\]). compare egdr's performance to fatty liver index (fli) and fib-4 in detecting mafld and predicting fibrosis. identify optimal egdr cut-offs for mafld detection (\<6 mg/kg/min) and advanced fibrosis staging (\<4 mg/kg/min). evaluate egdr's reclassification improvement (net reclassification index \>10%) over existing scores.

Eligibility criteria:
inclusion criteria: * age 18-65 years. * suspected/confirmed ms per idf criteria: * central obesity (waist circumference ≥94 cm \[men\]/≥80 cm \[women\]) plus ≥2 of: triglycerides ≥150 mg/dl. hdl \<40 mg/dl (men)/\<50 mg/dl (women). blood pressure ≥130/85 mmhg or antihypertensive treatment. fasting glucose ≥100 mg/dl or diabetes diagnosis. exclusion criteria: * other liver diseases (viral/autoimmune hepatitis). alcohol intake \>20 g/day (men) or \>10 g/day (women). pregnancy, malignancy, advanced cirrhosis. medications affecting metabolism (e.g., steroids)

Keywords: mafld egdr fibroscan
efficacy and safety of endoscopic injection of fibrin sealant versus endoscopic ligature for bleeding esophageal varices

Conditions: Esophageal and/or Gastric Varices

Summary: the purpose of this study was to assess whether endoscopic sclerotherapy with fibrin sealant was superior to ligature, with or without polidocanol, in achieving hemostasis in bleeding esophageal varices and preventing rebleeding. therapeutic success was defined as survival of the first seven days without clinically significant bleeding.


Eligibility criteria:
inclusion criteria: included in the study were patients with proven bleeding from esophageal varices due to liver cirrhosis: * with a minimum age of 18 years, * with bleeding symptoms (hematemesis, melena, hematochezia, hypotension, tachycardia) that had lasted not longer than 48 hours prior to hospital admission, * who were expected to be hospitalized for at least seven days, * who agreed to participate in the study. randomization did not take place if another therapy was medically indicated for any reason. exclusion criteria: patients were excluded from the study: * in whom introduction of an endoscope was not possible for technical reasons, * who had received an alternative endoscopic treatment to eradicate varices during the last three months (sclerotherapy, ligation), * who had proven additional fundus bleeding from varices or bleeding from a hypertensive gastropathy, * who had end stage tumor disease or end stage liver cirrhosis (child pugh class c with organ complications, such as hepatonephric syndrome, infected ascites etc.), * who were pregnant or breast feeding, * who had a known pulmonary disease combined with restricted lung function or right ventricular failure, * who had congenital or acquired coagulopathies of non-hepatic origin, * who were currently participating or had participated in another study during the past 30 days or had already been included in this study once, * who were treated with drugs to decrease portal vein pressure (somatostatin, somatostatin analogs, terlipressin, glycylpressin, except β-blockers and nitrates), * who had shown an allergic reaction to thrombin or aprotinin, * who had a heparin-induced thrombocytopenia type i or type ii.

Keywords: liver cirrhosis
evaluation of the effects of treatment of psycho-stimulant and cannabis-dependent users in israel

Conditions: Cannabis Dependence; Psychostimulant Dependence

Summary: this study evaluates the effects of psychological and pharmacological treatment of regular users of cannabis and psychostimulants in a treatment center (kfar izun) in israel. the participants will undergo psychological evaluation before and during treatment and follow up at 4 months. ten participants will undergo brain imaging of the dopamine receptor d2 in order to evaluate the effects of treatment on dopamine turnover in the brain. a control group of psychiatric in-patients undergoing treatment for psychiatric illness with be recruited from geha hospital in israel. it is predicted that successful treatment of regular users of cannabis will be resulted in improvement in anxiety, depression and psychotic symptoms as well as in upregulation of dopamine turnover in participants that will undergo brain imaging.

there is a significant number of cannabis and psychostimulant users that experience psychotic episodes and require psychiatric treatment. this study evaluates the effects of psychological and pharmacological treatment of regular users of cannabis and psychostimulants in a treatment center (kfar izun) in israel. the participants will undergo psychological evaluation before and during treatment and follow up at 4 months. ten participants will undergo brain imaging of the dopamine receptor d2 using \[i123\] ibzm in single photon emitted tomography (spect) before and after treatment in order to evaluate the effects of treatment on dopamine turnover in the brain. a control group of psychiatric in-patients undergoing treatment for psychiatric illness with be recruited from geha hospital in israel.

Eligibility criteria:
inclusion criteria: * cannabis dependence with or without history of psychosis. exclusion criteria: * pregnant women * under 18 * neurological damage * hiv positive * dependence on other drugs such as heroin * cocaine or alcohol

Keywords: cannabis psychostimulants psychosis